ProMetic Life Sciences (TSE:PLI) Rating Reaffirmed
They currently have a $4.50 target price per share on ProMetic Life Sciences (TSE:PLI). The target price by RBC Capital Markets would suggest a potential upside of 39.32% from the company’s previous stock close. This has been announced in a comprehensive report on Tuesday morning.
From a total of 7 analysts covering ProMetic Life Sciences Inc. (TSE:PLI) stock, 6 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that 100% of the ratings are positive. The highest target price is $7.4 while the lowest target price is $2.96. The mean of all analyst targets is $3.96 with a 24.77% above today’s ($3.31) stock price. ProMetic Life Sciences Inc. was the topic of 8 analyst reports since August 10, 2015 according to the firm StockzIntelligence Inc. RBC Capital Markets maintained shares on December 8 with “Outperform” rating.
The stock increased 2.80% or $0.09 on December 8, striking $3.31. Approximately 2.68 million shares of stock traded hands or 5.93% up from the average. ProMetic Life Sciences Inc. (TSE:PLI) has risen 47.77% since May 6, 2015 and is uptrending. It has outperformed by 48.56% the S&P500.
ProMetic Life Sciences Inc. is a Canada biopharmaceutical company. The company has a market cap of $1.92 billion. The Firm offers solutions in bioseparations, plasma-derived therapeutics and small-molecule drug development. It currently has negative earnings. ProMetic offers its technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens.